At MD Biosciences, we provide cutting-edge Parkinson's disease research through a diverse range of animal models. Our offerings include the traditional neurotoxin models, such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA), along with advanced genetic models. These models are designed to support translational studies with precise assessments and targeted endpoints, ensuring that your research advances effectively toward therapeutic breakthroughs.
Parkinson's Disease Models:
-
PD Neurodegeneration In Vitro Screening Assay
The Parkinson’s disease neurodegeneration assay utilizes primary neurons from rats to assess neuroprotection. After conditioning with alpha-synuclein, cultures are treated with test compounds and evaluated for the degeneration index. This endpoint is determined by comparing the neurite area and blebs.
Learn more about the PD neurodegeneration screening assay.
Download the PD model datasheet.
-
6OHDA In Vivo Model
The 6-hydroxydopamine (6OHDA) model is a unilateral lesion model for Parkinson’s disease used to study damage to the Nigro-Striatal pathway. Since 6OHDA cannot cross the blood-brain barrier when administered systemically, it is delivered via stereotaxic injection directly into targeted brain regions, including the substantia nigra (SN), ventral tegmental area (VTA), or striatum.
Paw placement test was performed in rats at various time points throughout the study. Vehicle treated animals were compared to test therapy. -
Acute MPTP In Vivo Model
The MPTP mouse model is a widely used model for studying Parkinson’s disease. MPTP is a lipophilic compound that easily crosses the blood-brain barrier and selectively targets degeneration of dopaminergic neurons, like the 6OHDA model. MPTP-induced animals also display motor abnormalities.
Total count of Th-IR immunoreactive cells in naive and MPTP-induced animals.
Scientific Data
HC staining with Tyrosine Hydroxylase (TH) antibody.
Figure A. Subgross image of Substantia Nigra sections showing reduction in number of TH-positive cells in the right hemisphere vs. the left intact hemisphere. Figure B. High magnification of TH-positive dopaminergic neurons. Figure C. Subgross image of TH-positive nerve fibers in section of striatum of the Left intact hemisphere contrasted to the lack of TH staining in the right hemisphere injected with 6-OHDA.
PD Models Datasheet
Please provide the following information for instant access to the datasheet.
READY TO DISCUSS YOUR PROGRAM?
At MD Biosciences, we’re not just a service provider—we’re your dedicated partner in drug development. With industry-leading expertise, we offer tailored study designs, translational models, and comprehensive endpoint assessments. Our commitment to short lead times and competitive pricing, combined with our deep scientific knowledge, ensures your research progresses efficiently and effectively. Collaborate with us to turn your scientific vision into reality.